



## BI1265162 | ENaC

inhaled ENaC inhibitor  
200 µg BID, phase II for CF (discontinued)  
building on amiloride pharmacophore  
Boehringer Ingelheim, Biberach, Germany




## asundexian | Factor XIa

oral Factor XIa inhibitor  
phase II for several indications  
structure-based *de novo* design  
Bayer AG, Wuppertal, Germany




## M4076 | ATM

ATM kinase inhibitor  
phase I for advanced solid tumors  
from HTS campaign  
Merck KGaA, Darmstadt, Germany




## AZD4604 | JAK1

selective inhaled JAK1 inhibitor  
several inhaled dose levels, phase I for asthma  
from re-opt. of oral JAK1 inhibitor  
AstraZeneca, Mölndal, Sweden



## JDQ443 | KRAS G12C

KRAS G12C inhibitor  
in dose esc., Ph. Ib/II for adv. solid tumors  
*de novo* design from literature starting point  
Novartis, Basel, Switzerland



## LPO200 (?) | IL-17A

oral IL-17A PPI modulator prodrug  
SAD and MAD studies, phase I for psoriasis  
structure-based *de novo* design  
LEO Pharma, Ballerup, Denmark